Novacyt « Terug naar discussie overzicht

nieuws Novacyt

222 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 » | Laatste
Biesaap
0
Maar de kans gaat klein zijn dat de aandeelhouders dit offer gaan aanvaarden gezien ook hun groot verlies afgelopen jaar.
voda
0
13 Jul Notice of cancelled AGM
in Board, Novacyt Group

Paris, France and Eastleigh, UK – 13 July 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (AGM), due to take place on 10 August 2023 has been cancelled and will be held by the end of October.

Paris, France and Eastleigh, UK – 13 July 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (AGM), due
to take place on 10 August 2023 has been cancelled and will be held by the end of October.
In the absence of a quorum at the AGM convened for 15 June 2023, a second meeting was planned for 10 August
2023. Following the recent announcement concerning the recommended cash offer for Yourgene Health plc and
following consent from the French court to delay approval of the FY2022 Accounts until 31 October 2023, the
Company now intends to hold an AGM later in 2023 enabling as many shareholders as possible to attend, which is
not possible during the summer months.
Forms of Proxy already received will unfortunately be void and full details of the new AGM and dates concerning
voting will follow in due course.

Voor meer, zie de link:

novacyt.com/notice-of-cancelled-agm/
voda
0
27 Jul Half Year Trading Update
in Board, Novacyt Group
Non-COVID sales growing quarter-on-quarter, significant progress in product development and non-organic growth strategy

Paris, France and Eastleigh, UK – 27 July 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited trading update for the six months ended 30 June 2023.

Half Year Trading Update

novacyt.com/half-year-trading-update-2/

novacyt.com/wp-content/uploads/2023/0...
voda
0
Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Half Year Trading Update

Non-COVID sales growing quarter-on-quarter, significant progress in product development and non-organic growth strategy

Paris, France and Eastleigh, UK - 27 July 2023 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its unaudited trading update for the six months ended 30 June 2023.

Financial highlights

· Group revenue for H1 2023 expected to be £3.3m of which £0.5m relates to COVID-19 (H1 2022: £16.5m of which £13.0m relates to COVID-19).

· Revenue for non-COVID-19 portfolio of £2.8m representing 85% of total revenues (H1 2022: £3.5m). As previously signalled, H1 2022 is a high comparator particularly in instrumentation sales linked to COVID sales.

· Non-COVID revenue continues to build with Q2 showing 3% growth over Q1 and 10% growth over Q4 2022.

· Opex in H1 2023 is expected to be in the region of £7.1m, a reduction of c.13% vs H2 2022, reflecting restructuring plans implemented in Q4 2022.

· Cash position at 30 June 2023 was £81.7m (H2 2022: £87.0m) and the Group remains debt free.

Well positioned for diversified organic and non-organic growth

Instrument sales have increased by over 65% in Q2 2023 compared with Q1 2023, showing signs of market improvement following the saturation that was seen during the COVID-19 pandemic, and non-COVID sales have increased incrementally over the last three quarters. The Company remains focused on building on the strength of its core business to deliver long-term sustainable growth, by expanding its product portfolio, driving international Research Use Only (RUO) sales and pursuing strategic business development opportunities. In line with this strategy, the Company announced on 3 July 2023 that it had made a recommended cash offer for Yourgene Health plc, an international integrated technologies and services business, enabling the delivery of genomic medicine. This is a key strategic milestone for Novacyt, which, upon anticipated completion by end of Q3 2023, will add scale and diversification to accelerate revenue growth and build long term value for the enlarged Group.

Strong R&D progress

During the period, the Company completed the development of six new multiplex RUO assays in the target therapeutic areas of gastrointestinal, respiratory, meningitis and other high-growth disease areas to meet the growing global demand for multiplex products that can detect multiple diseases in a single test. Management expects these products to begin commercialisation in the second half of 2023.

On 29 June, the Company received its seventh UK Coronavirus Test Device Approval (CTDA) for its PathFlow® COVID-19 Rapid Antigen Self-Test.

Focus on UKCA marking for UK clinical market

Given the importance of the UK market for Novacyt's clinical diagnostics products, the Company will prioritise UK Conformity Assessed (UKCA) marking for a selection of its new multiplex tests. The UKCA mark is replacing the CE mark for all in vitro diagnostic (IVD) products sold in the UK. Under UKCA, IVD manufacturers can continue to self-certify their products, which typically takes six to nine months compared to 18 to 24 months to achieve a CE mark under the new European In Vitro Diagnostic Regulation (IVDR). The Company is planning to self-certify two of its new multiplex products for respiratory and insect-borne diseases during H2 2023, with a further four expected in 2024.

In parallel, Novacyt is also progressing IVDR registration for its winter respiratory panel, genesig™ Real-time PCR SARS-CoV-2 Winterplex, which is expected to be completed by the end of 2024.

James McCarthy, Acting Group CEO of Novacyt, commented: "We have remained focused on delivering our strategy during the first half and have made strong progress in expanding our internal product portfolio and diversifying our business away from COVID, as demonstrated by the Group's highly complementary proposed acquisition of Yourgene. The launch of six new multiplex tests for the RUO market has significantly broadened our IVD portfolio and gives us access to additional near term revenues. With the UKCA offering a more favourable regulatory pathway, we expect to start the self-certification process for two of these news tests during the second half of 2023 and expect them to be available for clinical use in the UK in H1 2024."

www.voxmarkets.co.uk/rns/announcement...
voda
0
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

Acquisition update

Paris, France and Eastleigh, UK – 17 August 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, notes today’s announcement by Yourgene Health plc (“Yourgene”),
in relation to the recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned
subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023
(the “Acquisition”), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26
of the Companies Act 2006 (the "Scheme"). A circular in relation to the Scheme was published by Yourgene on 27
July 2023 (the "Scheme Document").

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meaning as set out in
the Scheme Document.

At the Court Meeting and the General Meeting held earlier today, convened in accordance with an order of the
Court dated 26 July 2023, all resolutions to approve and implement the Scheme were passed by the requisite
majorities of Yourgene's shareholders.

Yourgene’s full announcement can be found here: polaris.brighterir.com/public/yourgenehealth/news/rns/story/
xp39emw

The Acquisition remains subject to the satisfaction or (where applicable) waiver of the remaining Conditions and to
the further terms set out in Part III of the Scheme Document, including the Court sanctioning the Scheme at the
Court Sanction Hearing and the delivery of a copy of the Court Order to the Registrar of Companies. The expected
timetable of principal events for the implementation of the Scheme remains as set out in the Scheme Document.
The dates are indicative only and are subject to change. The dates will depend, among other things, on the date
upon which: (i) the Conditions are satisfied or (if capable of waiver) waived; (ii) the Court sanctions the Scheme;
and (iii) a copy of the Court Order is delivered to the Registrar of Companies.

Contacts
Novacyt SA +44 (0)23 8074 8830
James Wakefield, Non-Executive Chairman
James McCarthy, Acting Chief Executive Officer
Numis (Financial Adviser and Joint Broker to Novacyt and
Financial Adviser to Novacyt UK)

+44 (0)20 7260 1000

novacyt.com/acquisition-update/
Freddie Barnfield / Stuart Ord / Duncan Monteith / Jack McLaren
SP Angel Corporate Finance LLP (Nominated Adviser and Joint
Broker to Novacyt)

+44 (0)20 3470 0470

Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com /
y.petit@allegrafinance.com
voda
0
(“Novacyt”, the “Company” or the “Group”)
Notice of rescheduled AGM

Paris, France and Eastleigh, UK – 29 August 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that the Company’s Annual General Meeting (“AGM”) will
be held at 2pm CEST/1pm BST on 5 October 2023 as an open virtual meeting. Further details of the AGM will be
provided to shareholders in due course.

novacyt.com/notice-of-rescheduled-agm-4/
voda
1
(“Novacyt”, the “Company” or the “Group”)
Court sanction of the Scheme of Arrangement

Paris, France and Eastleigh, UK – 7 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, notes today’s announcement by Yourgene Health plc (“Yourgene”),
in relation to the recommended cash offer made by Novacyt UK Holdings Limited ("Novacyt UK"), a wholly-owned
subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023
(the “Acquisition”), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26
of the Companies Act 2006 (the "Scheme"). A circular in relation to the Scheme was published by Yourgene on 27
July 2023 (the "Scheme Document").

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meaning as set out in
the Scheme Document.

Further to the announcement made by Yourgene on 17 August 2023 in relation to the passing of the Resolutions
required to approve and implement the Scheme at the Court Meeting and the General Meeting, Yourgene has
announced that at the Court Sanction Hearing held earlier today the Court issued the Court Order sanctioning the
Scheme.

There has been no change to the expected timetable of principal events for the Acquisition set out in the Scheme
Document. Yourgene’s full announcement regarding the Court Sanction Hearing, including detailed next steps and
timetable, can be found here: polaris.brighterir.com/public/yourgen...

novacyt.com/notice-of-rescheduled-agm-4/
voda
0
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

Completion of acquisition of Yourgene Health plc and Board appointments

Acquisition adds scale and diversification to create a stronger global diagnostics business, with a complementary

suite of genomic technologies and services

Paris, France and Eastleigh, UK – 8 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces the completion of the acquisition by Novacyt UK Holdings
Limited ("Novacyt UK"), a wholly-owned subsidiary of Novacyt, of the entire share capital of Yourgene Health plc
(“Yourgene”), an international molecular diagnostic group (the “Acquisition”). The Acquisition has been
implemented by way of a scheme of arrangement between Yourgene and its shareholders under Part 26 of the UK
Companies Act 2006 (the "Scheme").

Further to the announcements made by the Company and Yourgene on 7 September 2023, that the Court had
sanctioned the Scheme, the Company is pleased to announce that, following delivery of the Court Order to the
Registrar of Companies today, the Scheme has now become Effective in accordance with its terms and accordingly,
Novacyt UK is now the owner of the entire issued share capital of Yourgene.

Yourgene’s announcement regarding the Scheme becoming Effective, including details on settlement and the
timing for the suspension of trading and subsequent delisting and cancellation of admission to trading on AIM for
Yourgene Shares can be viewed here: polaris.brighterir.com/public/yourgenehealth/news/rns/story/rmv3q2r

Yourgene is an international integrated technologies and services business, enabling the delivery of genomic
medicine. It primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and
screening solutions, for reproductive health and precision medicine. Yourgene's portfolio of in vitro diagnostic
products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic
Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays. Yourgene is headquartered
in Manchester, UK with offices in Taipei (divestment pending), Singapore, the U.S. and Canada.

The Acquisition is a key strategic milestone for Novacyt, creating a larger, specialist international diagnostics
company, adding scale and diversification to accelerate revenue growth and build long term value. The Enlarged
Group will have a broader product portfolio and complementary expertise, strengthening the Company’s market
position and enabling Novacyt to deliver more integrated solutionsto its customers. With Novacyt’sstrong financial
position and complementary resources, the Novacyt Board believes the Company is well-placed to accelerate the
growth of Yourgene’s core NIPT offering, Ranger® Technology and PCR portfolio to the benefit of the Enlarged
Group.

In accordance with the terms of the Acquisition, both Dr John Brown and Lyn Rees (Yourgene’s former Chairman
and CEO respectively) will join the board of Novacyt as non-executive and executive director respectively, first as
non-voting members, then as full members, subject to shareholder ratification at the next AGM.

James McCarthy, Acting Group CEO of Novacyt, commented: “The acquisition of Yourgene is an important strategic
milestone for Novacyt, broadening the scale and depth of our expertise and adding a complementary suite of
products and services in the exciting area of genomic medicine. I am delighted to welcome Lyn and his team to
Novacyt and look forward to working together as we continue to develop new innovative diagnostic solutions to
improve healthcare outcomes and drive the growth of the business.”

Commenting on the Acquisition, Lyn Rees, Chief Executive Officer of Yourgene, said:
"I am excited to join the Novacyt team and look forward to continuing the evolution of Yourgene and the Enlarged
Group. With the combined resources and expertise within the Enlarged Group, we are well placed to unlock the full
potential of our technologies and services and deliver greater value to our customers."

Capitalised terms used in this announcement shall, unless otherwise defined, have the same meanings as set out
in Part VII of the scheme document published by Yourgene on 27 July 2023 in connection with the Scheme.

Regulatory Disclosures
Save for the information set out above and below, there are no further disclosures to be made in accordance with
Rule 17, Schedule Two (g) of the AIM Rules for Companies in respect of the appointments of Mr John Robert Brown,
aged 68, and Mr Lyn Dafydd Rees, aged 50.

Voor meer, zie link:

novacyt.com/completion-of-acquisition...
voda
0
11 Sep De-listing and cancellation of trading of Yourgene Shares
in Board, Novacyt Group

Paris, France and Eastleigh, UK – 11 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes today’s announcement by Yourgene Health plc (“Yourgene”), in relation to the recommended cash offer made by Novacyt UK Holdings Limited (“Novacyt UK”), a wholly-owned subsidiary of Novacyt, for the entire issued and to be issued share capital of Yourgene announced on 3 July 2023 (the “Acquisition”), which is to be effected by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the “Scheme”).

Further to the announcement made by Yourgene on 8 September 2023 that the Scheme has now become Effective in accordance with its terms, Yourgene has today announced that, following an application to the London Stock Exchange, the admission to trading on AIM of Yourgene Shares has been cancelled with effect from 7.00 a.m. today, 11 September 2023.

De-listing and cancellation of trading of Yourgene Shares

novacyt.com/de-listing-and-cancellati...
voda
0
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)
Notice of Half Year 2023 Results and Investor Presentation

Paris, France and Eastleigh, UK – 13 September 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that it will report its unaudited financial results for the six
months ended 30 June 2023 on Thursday, 28 September 2023.

Investor webinar

An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, Steve Gibson, Group Finance
Director and Lyn Rees, Executive Director and former CEO of Yourgene, covering the H1 2023 results will take place
at 12.30pm BST on Thursday, 28 September 2023.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A
session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor
Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation.
Automated French subtitling will be available throughout the presentation.
Investors can sign up for the webinar via:

www.investormeetcompany.com/novacyt-s...
Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

novacyt.com/notice-of-half-year-2023-...
voda
1
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

AGM voting

Paris, France, and Eastleigh UK – 14 September 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that shareholders are now able to vote for the Company’s
rescheduled Annual General Meeting (“AGM”), which will be held at 1pm BST/2pm CEST on 5 October 2023 as an
open virtual meeting.

The Company’s Annual General Meeting (“AGM”) will be held exclusively as an open online meeting at 1pm
BST/2pm CEST on Thursday, 5 October 2023. As this is a rescheduled meeting, all previous votes are now void and
all shareholders must resubmit their votes.

As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary
resolutions. All materials can be found at www.novacyt.com/investors.
Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the
Notice of the AGM.

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at
least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting
rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions
set out below.

Shareholders can vote in advance of the AGM by:
• Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it
and returning it together with evidence of their shareholding which must be in the form of a share
certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex
09, or via email to the following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later
than 2 October 2023 inclusive.
• Voting on-line using the Votaccess portal www.actionnaire.cic-marketsolutions.eu if securities held
on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis,
Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank,
Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 15 September 2023
to 4 October 2023 2pm BST/3pm CEST.
• Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such
as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

Shareholders can register for the AGM and access the online meeting by visiting
novacytagm23.eventcaster.co.uk. Registration must be accompanied by formal evidence of shareholding.
As this is a rescheduled meeting, all previous registrations are now void and all shareholders must re-register.
Following registration approval, shareholders will be able to virtually attend the AGM and vote online during the
meeting if they wish, providing formal evidence of holding has been provided prior to the meeting.

Shareholders who have voted (through a proxy, via their broker, nominee, bank, authorised intermediary,
Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM online but will not be able to vote
twice.

Following the meeting, a recording of the AGM will be available on the Company’s website at
www.novacyt.com/investors.

novacyt.com/agm-voting-4/
voda
0
Please find the attached RNS issued this morning.

An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, Steve Gibson, Group Finance Director and Lyn Rees, Executive Director and former CEO of Yourgene, covering the H1 2023 results will take place at 12.30pm BST today.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Automated French subtitling will be available throughout the presentation.

Investors can sign up for the webinar via:

www.investormeetcompany.com/novacyt-s...

Kind regards,

Mandy Cowling

Corporate and Investor Relations Manager

mandy.cowling@novacyt.com

Novacyt Group

www.novacyt.com

LinkedIn

Mobile: +44 (0) 7785 541 259

York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG?
voda
0
Mandy Cowling mandy.cowling@novacyt.com
Bijlagen
08:06 (25 minuten geleden)
aan

Please find the attached RNS issued this morning.

Kind regards,

*should you wish to be removed from this email circulation, please advise by return.

Mandy Cowling

Corporate and Investor Relations Manager

mandy.cowling@novacyt.com

Novacyt Group

www.novacyt.com

LinkedIn

Mobile: +44 (0) 7785 541 259

York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG?

11 Oct AGM voting
in Board, Novacyt Group

Paris, France, and Eastleigh UK – 11 October 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that shareholders are now able to vote for the Company’s rescheduled Annual General Meeting (“AGM”), which will be held at 1pm BST/2pm CEST on 26 October 2023 as an open meeting in Paris. All previous votes remain valid for all meetings subsequently convened with the same agenda.

As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary resolutions. All materials can be found at www.novacyt.com/investors.

Shareholders wishing to attend the General Meeting in person may:

For shareholders whose shares are registered with CIC: present themselves on the day of the General Meeting, with proof of identity.

Shareholders whose shares are registered in bearer form: ask the authorised intermediary who manages their securities account to send them a proof of shareholding or a letter of representation, evidencing that they hold shares of Novacyt.
Shareholders can also request an admission card in advance (a) from CIC Services, by post to the following address: CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email to the following address: serviceproxy@cic.fr; or (b) on the secure VOTACCESS platform accessible via the website www.actionnaire.cic-marketsolutions.eu.

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the Notice of the AGM.

AGM voting

novacyt.com/agm-voting-5/
voda
0
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

AGM voting

Paris, France, and Eastleigh UK – 11 October 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that shareholders are now able to vote for the Company’s
rescheduled Annual General Meeting (“AGM”), which will be held at 1pm BST/2pm CEST on 26 October 2023 as an
open meeting in Paris. All previous votes remain valid for all meetings subsequently convened with the same
agenda.

As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary
resolutions. All materials can be found at www.novacyt.com/investors.
Shareholders wishing to attend the General Meeting in person may:

- For shareholders whose shares are registered with CIC: present themselves on the day of the General
Meeting, with proof of identity.
- Shareholders whose shares are registered in bearer form: ask the authorised intermediary who manages
their securities account to send them a proof of shareholding or a letter of representation, evidencing that
they hold shares of Novacyt.

Shareholders can also request an admission card in advance (a) from CIC Services, by post to the following address:
CIC Services Assemblées Générales, 6 avenue de Provence 75452 Paris Cedex 09, or by email to the following
address: serviceproxy@cic.fr; or (b) on the secure VOTACCESS platform accessible via the website
www.actionnaire.cic-marketsolutions.eu.

Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the
Notice of the AGM.

Shareholders can vote in advance of the AGM by:

• Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it
and returning it together with evidence of their shareholding which must be in the form of a share
certificate (attestation) or a letter of representation from their broker, nominee, bank or authorised
intermediary, either by post to the following address: 6 avenue de Provence 75452 Paris Cedex 09, or via
email to the following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later than 23
October 2023 inclusive.

• Voting on-line using the Votaccess portal www.actionnaire.cic-marketsolutions.eu if securities held
on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis,
Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank,
Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 11 October 2023
to 25 October 2023 2pm BST/3pm CEST.

• Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such
as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.
Shareholders can register to view the AGM online by visiting novacytagm23.eventcaster.co.uk, however,
they will be unable to vote during the meeting. Registration must be accompanied by formal evidence of
shareholding.

Following the meeting, a recording of the AGM will be available on the Company’s website at
www.novacyt.com/investors.

novacyt.com/agm-voting-5/
voda
0
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

Result of AGM

Paris, France, and Eastleigh UK – 26 October 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that all resolutions proposed at the ordinary general
meeting part of the Company’s Annual General Meeting (AGM), held today, were duly passed.

As part of the AGM, the Company also met today to hold an extraordinary general meeting. The meeting was not
deemed quorate due to the minimum number of voting rights under French company law not being present or
represented at the meeting. Consequently, the meeting did not take place.

Following the AGM, Dr John Brown CBE and Lyn Rees have now formally joined the Novacyt Board, as Non-Executive
and Executive Director respectively.

The results of the AGM voting will be made available on the Company's website.

novacyt.com/agm-voting-5/
voda
0
Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)
IVDR certification achieved for DPYD genotyping assay
One of the first products of its kind to conform with new IVDR requirements

Paris, France, and Eastleigh and Manchester, UK – 7 November 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV;
AIM: NCYT), an international specialist in clinical diagnostics, confirms IVDR accreditation under the new EU
requirements of the In Vitro Diagnostic Regulation (“IVDR”) for its DPYD genotyping assay, which supports the
identification of cancer patients at risk of suffering a severe, and potentially life-threatening, reaction to common
chemotherapy.

The Yourgene® DPYD assay is used to identify patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency,
through the rapid detection of six clinically relevant variants in the DPD enzyme. Patients with a DPD deficiency
have a high risk of severe, and sometimes lethal, side effects following the administration of 5-Fluorouracil (5-FU),
a widely used chemotherapy agent used in the treatment of many cancers including colorectal, head and neck,
breast, pancreatic and stomach cancer.

An estimated two million people globally are treated with fluoropyrimidines (including 5-FU) each year1
, with between 10-30% of these patients suffering severe side effects associated with DPD deficiency2
.
DPYD genotyping for 5-FU toxicity has been adopted in many countries internationally with screening introduced into cancer care linical pathways following government reimbursement in England, Wales, Germany, Spain, Belgium and the
Ontario province of Canada. The screening enables clinicians to reduce the risk of increased toxicity from 5-FU
exposure in these patients by treatment with a lower dose, or with an alternate drug therapy where indicated.
The Yourgene® DPYD assay is a Class C in vitro medical device under IVDR and is intended for use by healthcare
professionals within a molecular or oncology laboratory environment.

The new IVDR ensures that in vitro diagnostic devices manufactured for sale in the EU are assessed against stringent
quality, safety and performance requirements. Manufacturers must provide, among other things, considerable
evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the devices. The
DPYD assay was assessed by BSI, an independent conformity assessment body (the “Notified Body”) and was shown
to conform to the new regulations.

The DPYD assay is the first product within the now enlarged Novacyt product portfolio to conform to the new EU
IVDR and is one of the first pharmacogenomics tests in the market, and the only assay for the rapid detection of
the six clinically relevant variants in the DPD enzyme, as defined by the CPIC* guidelines, to conform to IVDR. The
Directors of Novacyt believe that conformity with IVDR provides clinicians and patients with additional confidence
in the high-quality and accuracy of this test, which is increasingly becoming an essential screening requirement
ahead of cancer patient treatment.

Commenting James McCarthy, Acting Chief Executive Officer, said: “We are delighted to announce the first
conformity of one of our products to the new EU regulations for in vitro diagnostic products. This success reflects
the high-quality of the product in terms of both performance and safety, and follows a rigorous review by our
Notified Body. It is a clear market advantage to have our product as the first assay to detect DPD deficiency to
conform to IVDR, particularly as more and more countries in Europe and elsewhere are adopting this form of
screening as their recommended procedure ahead of chemotherapy treatment.”

Sources
1 D. Meulendijks et al./Cancer Treatment Reviews 50 (2016) 23–34
2 Cancer Research UK bit.ly/2kLn1uT

*CPIC Guidelines (Clinical Pharmacogenetics Implementation Consortium) provides clinical dosing

recommendations based on DPYD genotype for patients cpicpgx.org/guidelines/guideline-for-
fluoropyrimidines-and-dpyd/

novacyt.com/ivdr-certification-achiev...
voda
0
Met dank aan:

quote:

Louis7 schreef op 27 december 2023 12:52:

21 Dec Update on Taiwan laboratory.

Paris, France, Eastleigh and Manchester, UK – 21 December 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an update to the conditional disposal of its laboratory in Taiwan, which it acquired as part of the Yourgene Health plc (“Yourgene”) acquisition completed on 8 September 2023.

On 13 June 2023, Yourgene announced the conditional divestment of its Taiwanese subsidiary, Yourgene Health Taiwan Co Ltd (“Yourgene Health Taiwan”), to INEX Innovate Pte Ltd (“INEX”), a Singapore-based molecular diagnostics company focused on women’s and fetal health, for proceeds of up to US$4m (approximately £3.2m).

Lees verder op:
novacyt.com/update-on-taiwan-laborato...
voda
0
Novacyt S.A.

("Novacyt", the "Company" or the "Group")

DHSC Claim update - Pre-Trial Review

Paris, France, and Eastleigh and Manchester, UK - 19 April 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, provides an update regarding its legal proceedings against the Department of Health and Social Care ("DHSC").

As previously announced, the Company and its subsidiary Primer Design Ltd are party to litigation with the DHSC. The trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.

The court has listed the Pre-Trial Review to be heard on 30 April 2024. This is part of the normal litigation process and is predominantly concerned with administrative preparations for trial.

The court will also hear an application by the DHSC for summary judgment in relation to one aspect of its claim, as part of which the DHSC is seeking judgment to be entered for the full value of its claim. Having taken legal advice, the Company considers this application to be very weak with low prospects of success, and is confident that the court will dismiss the application. It is not known when the court will give judgment in relation to the application. It may be during or at the end of the Pre-Trial Review, or a short time thereafter.

The Company will announce the outcome of the application in due course.

www.lse.co.uk/rns/NCYT/dhsc-claim-upd...
voda
0
Novacyt S.A.

("Novacyt", the "Company" or the "Group")

Long Term Incentive Plan

2024 Performance Share Awards

Paris, France, and Eastleigh and Manchester, UK - 23 April 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has made an allocation of share options as part of its Long Term Incentive Plan ("LTIP").

Shareholders approved the issue of options over new ordinary shares of €1/15 each in the Company to employees at the Company's combined general meeting held on 18 October 2021. Under the terms of the LTIP, the Board may determine the percentage award for each qualifying executive each year. The Board may, at its absolute discretion, decide to reduce the total number of shares held under an award and/or seek to recover from a participant, shares and/or cash that has already vested, been paid and/or been acquired on the exercise of an option.

2024 Performance Share Awards

The 2024 Performance Share Awards (structured as nil-cost options1) are being made to the executive management team only, which currently comprises five members. The performance shares will vest ("Vest") subject to the Company achieving Total Shareholder Return ("TSR") growth conditions in a three financial year period which began on 1 January 2024 (the "Performance Period") as follows:

Voor meer, zie link:

www.lse.co.uk/rns/NCYT/long-term-ince...
222 Posts, Pagina: « 1 2 3 4 5 6 7 8 9 10 11 12 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 23 mei 2024 17:38
Koers 0,786
Verschil +0,056 (+7,67%)
Hoog 0,810
Laag 0,720
Volume 478.082
Volume gemiddeld 200.139
Volume gisteren 32.598

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront